Terumo subsidiary MicroVention announced that it began the U.S. launch of its LVIS EVO intraluminal support device.
The device is now available in the U.S. for the treatment of wide-neck intracranial aneurysms. Aliso Viejo, California-based MicroVention first launched the device in Europe in 2019, selling more than 12,000 units since.
According to a news release, LVIS EVO is the first fully visible coil-assist-intracranial stent available on the U.S. market.
The device features enhanced visualization, optimized opening and precise placement with DFT wire construction and advanced braid design. With enhanced visualization, it also provides wall apposition confirmation, with full visibility of the stent’s entire body under fluoroscopy.
With an optimized braid angle, the device allows for improved opening across its entire length. Its precise placement offers controlled delivery and development, plus the ability to resheath up to 80% of the device’s length. This entire portfolio works with MicroVention’s existing Headway 17 advanced microcatheter and Scepter C and XC occlusion balloons.
“Today’s announcement underscores MicroVention’s commitment to delivering groundbreaking solutions for hemorrhagic stroke treatment,” said Carsten Schroeder, president and CEO of MicroVention. “MicroVention continues to lead the way in both hemorrhagic and ischemic stroke care. This achievement is a testament to our collaboration with leading physicians worldwide. By identifying the evolving needs in patient care and transforming those insights into innovative technologies, we are able to save lives and improve outcomes.”
